Table 2.
Count (%) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
The Netherlands | Belgium | Sweden | |||||||||||||
|
|
|
|||||||||||||
Stage II2 | Stage II2 | Stage II2 | |||||||||||||
|
|
|
|||||||||||||
Basic characteristics1 | Total | Total | Low-risk | High-risk | Stage III | Total | Total | Low-risk | High-risk | Stage III | Total | Total | Low-risk | High-risk | Stage III |
Total | 31879 | 16206 | 9733 | 5379 | 15673 | 14847 | 7921 | 5244 | 2231 | 6926 | 13518 | 7073 | 3085 | 3858 | 6445 |
| |||||||||||||||
Sex | |||||||||||||||
| |||||||||||||||
Men | 16527 (52) | 8260 (51) | 5174 (53) | 2515 (47) | 8267 (53) | 7618 (51) | 4099 (52) | 2871 (55) | 1014 (45) | 3519 (51) | 6600 (49) | 3441 (49) | 1590 (52) | 1786 (46) | 3159 (49) |
| |||||||||||||||
Women | 15352 (48) | 7946 (49) | 4560 (47) | 2864 (53) | 7406 (47) | 7229 (49) | 3822 (48) | 2373 (45) | 1217 (55) | 3407 (49) | 6918 (51) | 3632 (51) | 1495 (48) | 2072 (54) | 3286 (51) |
| |||||||||||||||
Mean age (±SD) | 71 (11) | 72 (11) | 71 (11) | 72 (11) | 69 (11) | 72 (11) | 73 (11) | 73 (11) | 74 (11) | 71 (12) | 73 (11) | 73 (11) | 73 (11) | 74 (11) | 72 (12) |
| |||||||||||||||
Age at diagnosis | |||||||||||||||
| |||||||||||||||
<60 | 4912 (15) | 2147 (13) | 1348 (14) | 638 (12) | 2765 (18) | 2062 (14) | 970 (12) | 655 (12) | 264 (12) | 1092 (16) | 1671 (12) | 755 (11) | 324 (11) | 415 (11) | 916 (14) |
| |||||||||||||||
60–69 | 8842 (28) | 4223 (26) | 2625 (27) | 1301 (24) | 4619 (29) | 3330 (22) | 1663 (21) | 1118 (21) | 448 (20) | 1667 (24) | 3063 (23) | 1494 (21) | 699 (23) | 763 (20) | 1569 (24) |
| |||||||||||||||
70–79 | 10869 (34) | 5728 (35) | 3459 (36) | 1891 (35) | 5141 (33) | 4810 (32) | 2606 (33) | 1755 (33) | 707 (32) | 2204 (32) | 4740 (35) | 2538 (36) | 1132 (37) | 1365 (35) | 2202 (34) |
| |||||||||||||||
80+ | 7256 (23) | 4108 (25) | 2302 (24) | 1549 (29) | 3148 (20) | 4645 (31) | 2682 (34) | 1716 (33) | 812 (36) | 1963 (28) | 4044 (30) | 2286 (32) | 930 (30) | 1315 (34) | 1758 (27) |
| |||||||||||||||
Tumor location | |||||||||||||||
| |||||||||||||||
Right | 15846 (51) | 8381 (53) | 4882 (51) | 2898 (56) | 7465 (49) | 7017 (50) | 3876 (52) | 2399 (48) | 1240 (59) | 3141 (48) | 7877 (58) | 4252 (60) | 1780 (58) | 2387 (62) | 3625 (56) |
| |||||||||||||||
Left | 15138 (49) | 7319 (47) | 4620 (49) | 2252 (44) | 7819 (51) | 7084 (50) | 3639 (48) | 2612 (52) | 853 (41) | 3445 (52) | 5632 (42) | 2819 (40) | 1305 (42) | 1469 (38) | 2813 (44) |
| |||||||||||||||
Type of surgery | |||||||||||||||
| |||||||||||||||
Open resection | 17872 (56) | 9025 (56) | 4904 (50) | 3555 (66) | 8847 (57) | – | – | – | – | – | 12055 (90) | 6282 (89) | 2658 (87) | 3513 (92) | 5773 (90) |
| |||||||||||||||
Laparoscopy | 13966 (44) | 7162 (44) | 4820 (50) | 1816 (34) | 6804 (43) | – | – | – | – | – | 1377 (10) | 751 (11) | 407 (13) | 325 (8) | 626 (10) |
| |||||||||||||||
Treatment | |||||||||||||||
| |||||||||||||||
Surgery alone | 20964 (66) | 14788 (91) | 9304 (96) | 4443 (83) | 6176 (39) | 8182 (55) | 5992 (76) | 4258 (81) | 1374 (62) | 2190 (32) | 9130 (68) | 6239 (88) | 2961 (96) | 3153 (82) | 2891 (45) |
| |||||||||||||||
Surgery+ACT3 | 10915 (34) | 1418 (9) | 430 (4) | 936 (17) | 9497 (61) | 6665 (45) | 1929 (24) | 986 (19) | 857 (38) | 4736 (68) | 4388 (32) | 834 (12) | 124 (4) | 705 (18) | 3554 (55) |
Unknown tumor location: 895(3%) in The Netherlands; 746 (5%) in Belgium; 9 (<1%) in Sweden; Unknown type of surgery: 41 (<1%) in The Netherlands; 86 (<1%) in Sweden. These unknown data were similarly distributed by categories of patients’ characteristics.
Low-/high-risk could not be classified due to missing information of prognostic factors: The Netherlands 3%, Belgium 3% and Sweden 1%.
Time from surgery to ACT was: Median (interquartile range) = 6 (5–8) weeks in Belgium and 7 (6–8) weeks in Sweden.
Abbreviations: ACT, Adjuvant chemotherapy; –, data no available.